Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS: In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1). The primary end points for part 1 were the resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis. RESULTS: Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001). Results for the three secondary outcomes that were included in the plan to adjust for multiple testing were as follows: combined resolution of steatohepatitis and reduction in liver fibrosis was reported in 32.7% of the patients in the semaglutide group and in 16.1% of those in the placebo group (estimated difference, 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001). The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001). Mean changes in bodily pain scores did not differ significantly between the two groups. Gastrointestinal adverse events were more common in the semaglutide group. CONCLUSIONS: In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent study reported significant effects on the resolution of MASLD without worsening of fibrosis, but also significant improvements in fibrosis without worsening of MASLD after 72 weeks of treatment with semaglutide.84”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [84]
In the citing paper
“Part 1 of a phase III trial investigating semaglutide for the treatment of MASH demonstrated resolution of steatohepatitis with no worsening of fibrosis in 63% of the semaglutide group, compared with 34% in the placebo group (68).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“In addition, 37% of the semaglutide group showed improvement in fibrosis without worsening of steatohepatitis, compared with 23% in the placebo group.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“As for resmitirom, semaglutide is indicated for MASH patients with moderate to advanced liver fibrosis, but not liver cirrhosis (53).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [53]
In the citing paper
“In the ESSENCE phase 3 trial, semaglutide showed a significant antifibrotic effect in patients with MASH and stage F2–F3 fibrosis (225).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [225]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 501–600 of 1,000
Loss of Hepatocyte FOXA3 Improves MASH and Atherosclerosis in Hyperlipidemic Ldlr-Deficient Mice
Wang, H., Hu, S., Wang, J., Gopoju, R., Lin, L., Gunawardana, L., Wang, X., Yin, L., & Zhang, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031468 · Cited by 1
Kabashima, M., Hasuzawa, N., Wang, L., Rikitake, J., Nomura, S., Niimoto, T., Tokubuchi, R., Moriyama, S., Gobaru, M., Inoguchi, Y., et al. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168180 · Cited by 1
Sivakumar, W., O'Connor, D., Shabana, H., Crusher, R., Tuite, C., O’Sullivan, C., Houlihan, D. D., Stack, W., & O’Boyle, C. (2026) · Scientific Reports · doi:10.1038/s41598-026-39142-x · Cited by 1
“In adults with non-cirrhotic MASLD who meet the accepted criteria, bariatric surgery should be considered 9 .”
Ariyathanapong, N., Ploypradith, K., Yoshimura, P. K., Thedrattanawong, C., Wüestefeld, T., Leelahavanichkul, A., Jin, T., Mao, L., Fang, R. H., Lee, Y., et al. (2026) · Smart Materials in Medicine · doi:10.1016/j.smaim.2026.02.001 · Cited by 3
Impact of Sex on Plasma Biomarkers in ob/ob Mice
Suh, Y., & Kim, K.-E. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041712 · Cited by 1
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
Cardiometabolic and Diabetes Management in Older Adults
Marion, W., & Neeland, I. J. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.005 · Cited by 1
Metabolic Liver Disease Beyond the Liver
Gastaldelli, A., Tacke, F., & Holleboom, A. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.003 · Cited by 1
Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America
Oliveira, C. P., Pessôa, M. G., Díaz, L. A., Arab, J. P., Gadano, A. C., & Arrese, M. A. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.014 · Cited by 1
Metabolische Lebererkrankungen bei Adipositas
Horn, P., & Tacke, F. (2026) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2722-1114 · Cited by 1
Roberts, S. K., Díaz, L. A., & Castellanos-Fernández, M. I. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.012 · Cited by 1
Song, B. G., Goh, M. J., Kang, W., Gwak, G., Paik, Y., Choi, M. S., Lee, J. H., & Sinn, D. H. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102199 · Cited by 2
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
“Outcomes were no different in those with T2D compared to those without, with 56% of the cohort exhibiting T2D [45].”
Obesity, metabolic health status, and adverse outcomes in men and women
Ananda, R. A., Solomon, B. D., Nicholls, S. J., & Ray, K. K. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101556 · Cited by 2
“Improved end-organ hard outcomes using these therapies in individuals with obesity and established ASCVD[17], HF with preserved ejection fraction[18,43], MASH or fibrosis[44,45], and CKD,[46] demonstrate the modifiability of multiple health outcomes resulting from obesity.”
Zhou, X., Zheng, M., & Wong, R. J. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.234 · Cited by 1
Current management of MASLD in type 2 diabetes
Fernández‐Garibay, V. M., Sarabia-Chao, V., & Chávez-Tapia, N. C. (2026) · HORMONES · doi:10.1007/s42000-026-00763-6 · Cited by 1
Knorr, J. P., Reese, R., Serbantez, M., & Lin, K. P. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag095 · Cited by 2
Liver disease and general anesthesia: what the anesthesiologist needs to know
Flick, M., Sebode, M., Eichlseder, M., & Saugel, B. (2026) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001648 · Cited by 1
Gouda, P., Allyn, N., Belin, R. M., Borentain, M., Butler, J., Curtis, L. H., George, J. T., Hornik, C. P. V., Jackman, J. G., Jessup, M. L., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102713 · Cited by 2
Merrild, C., Johansen, V. B. I., Clemmensen, C., & Ranea‐Robles, P. (2026) · The Journal of Physiology · doi:10.1113/jp289817 · Cited by 1
Alkhouri, N., Chalasani, N., Younossi, Z. M., Loomba, R. S., Bansal, M. B., Lazarus, J. V., Moussa, S., Patil, R., Schattenberg, J. M., Gawrieh, S., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70639 · Cited by 1
Tsutsumi, T., Tang, N. S. Y., Ng, C. H., Suzuki, H., Syn, N. L., Sasikumar, N. A., Ho, G. J. K., Chua, D., Tioh, J. K., Pramotedham, T., et al. (2026) · Med · doi:10.1016/j.medj.2026.101077 · Cited by 3
Self-citationLiver disease: screening for the elusive adversary
Abeysekera, K. W. M., & Buchanan, R. M. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00598-2 · Cited by 1
MASH and liver fibrosis: Clinical trials to watch
Zhang, X., & Wong, V. W. (2026) · Med · doi:10.1016/j.medj.2026.101069 · Cited by 1
Evidence-Based Management of MASLD: GRADE Evaluation of Pharmacological Therapies
Karavia, E. A., Pittaras, A. E., Andreopoulou, O., Hatziri, A., Makrydimitri, A., Anagnostopoulos, D., Vareltzis, P. K., & Kypreos, K. E. (2026) · Pharmaceuticals · doi:10.3390/ph19040605 · Cited by 1
Metabolic dysfunction-associated steatotic liver disease in Asia: implications on management
Lai, K. N., & Wong, V. W. (2026) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-167 · Cited by 2
Stupalkowska, W., Henney, A. E., Riley, D. R. J., Sheu, E. G., Alam, U., & Cuthbertson, D. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70757 · Cited by 1
Endocrinology: What You May Have Missed in 2025
Escudero, C., Havranek, K., Cruz, M. M., & Batch, B. C. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-00925 · Cited by 1
Gastroenterology/Hepatology: What You May Have Missed in 2025
AlAwadhi, H., Chang, N. H., Jogendran, M., & Bretthauer, M. (2026) · Annals of Internal Medicine · doi:10.7326/annals-26-01058 · Cited by 1
Lifespan approaches for the prevention and management of steatotic liver disease
Zelber‐Sagi, S., Ivancovsky-Wajcman, D., Kugelmas, C., Weinstein, A. A., Wong, V. W., Castéra, L., Moore, J. B., Mouzaki, M., Hallsworth, K., Paik, J. M., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01198-5 · Cited by 2
Glucagon-like peptide-1 receptor agonists across anti-inflammation
Chen, D. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101474 · Cited by 1
Yihong, J., Gu, H., Wang, M., Miao, Y., Gao, C., Zhang, J., & Luo, L. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102598 · Cited by 1
“Despite the recent approval of agonists targeting the thyroid hormone receptor beta (THR β ) (i.e., resmetirom) and glucagon-like peptide-1 receptor (GLP-1R) (i.e., semaglutide) for MASH, only about one-quarter of patients show histological improvements in fibrosis [7,8].”
Obesity management medications for the surgeon
Harris, M., Mahdi, S., Fairfield, C. J., Brown, L. R., Wadley, M., & Miras, A. D. (2026) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103307 · Cited by 1
Johansson, E., Wilding, J. P. H., Upadhyay, N., van Hest, N., Kirk, M., Spaepen, E., Zimner‐Rapuch, S., Annemans, L., & Bays, H. E. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2646078 · Cited by 1
Romeo, M., Basile, C., Martinelli, G., Nardo, F. D., Napolitano, C., Gregorio, A. D., Vaia, P., Puorto, L. D., Indipendente, M., Federico, A., et al. (2026) · Cancers · doi:10.3390/cancers18081316 · Cited by 1
Jiménez-González, C., Vélez, P. A., Cayon, L., García-Garrido, A. B., Garmilla, N. F., Cuadrado, A., Iruzubieta, P., & Crespo, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15093259 · Cited by 1
“The phase III trial of resmetirom demonstrated histological improvement in patients with MASH and fibrosis [9], while glucagon-like peptide-1 receptor agonists such as semaglutide have also shown promising results in this population [10].”
Dai, W., & Zhang, G. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70701 · Cited by 1
“This concern is consistent with the Phase 3 ESSENCE trial reported by Sanyal et al., in which histologic fibrosis improvement became evident only after 72 weeks, underscoring the importance of adequate treatment duration when assessing whether NITs can reflect fibrosis response [2].”
Müller, L., Ceriani, L., Harris, D. T., Wolfson, T. J., Batakis, D., Agni, R. M., Covarrubias, Y., Pepin, K., Ehman, R. L., Heilman, J. A., et al. (2026) · Radiology · doi:10.1148/radiol.253243 · Cited by 2
Choi, Y.-J., Bea, S., Chung, S. W., Seo, H.-T., Rhee, T., Park, C. S., Lee, H., Han, K. D., Kim, Y. J., Kim, H. K., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag254 · Cited by 2
Calleri, A., Yazarkan, Y., Liu, K., Kassmeyer, B. A., Lennon, R. J., Rattan, P., Seid, A., Bernard, M. E., Singh, G., Deyo-Svendsen, M. E., et al. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02718-y · Cited by 1
“Importantly,evenwithlowerAIengage-ment,theLEgroupstilldemonstratedhigheroddsofCLDdiagnosis comparedwiththecontrolgroup,underscoringtheclinicalrelevanceof identifyingearlierstagesofliver fi brosis as emerging anti fi brotic therapies hold promise for halting disease progression 15,16 .”
Vaz, K., Clayton‐Chubb, D., Kemp, W. W., Roberts, S. K., & Majeed, A. (2026) · The Medical Journal of Australia · doi:10.5694/mja2.70195 · Cited by 1
Role of activity and fibrosis in the MASLD atherogenic momentum through advanced lipidomics
Blanco-Echevarría, A., Segovia, R. C., Herraiz, C. G., Izquierdo, B. G., Guadalix, S., Carreras, M. P., Gil, Y. R., Martínez, M. D. C., Amigó, N., D’Avola, D., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0343134 · Cited by 1
“Several agents targeting hepatic steatosis and inflammation—such as GLP-1 receptor and dual GLP-GIP receptor agonists—have shown promise in improving cardiovascular risk markers in MASLD, independent of fibrosis regression [38,39].”
Jensen, E. L., Thiele, M. S., Torp, N., Johansen, S., Hansen, J. K., Sørensen, M. D., Hansen, C. D., Hovland, M., Andersen, M. L., Semmler, G., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.04.027 · Cited by 1
Berardicurti, A., D’Andrea, S., Cipollone, F., Berardicurti, O., Schiavone, C., & Boccatonda, A. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04384-0 · Cited by 1
Bazan, A., Plichta, O., & Radzinska, N. (2026) · Cureus · doi:10.7759/cureus.108965 · Cited by 1
“Semaglutide should, therefore, be described as a stage-specific option for selected non-cirrhotic patients in a defined clinical context, with final positioning dependent on current guidance and local regulatory status, rather than as a general treatment for MASLD across all stages [17,18].”
Steatotic liver disease and cardiovascular-kidney-metabolic syndrome: A case study
Kolodziejczyk, H., & Ignatiev, E. (2026) · Nursing · doi:10.1097/nsg.0000000000000389 · Cited by 1
He, K., Chen, F., Shao, R., Jiang, W., Gu, W., Huang, Z., Gan, Y., Wang, Y., Wu, H., Zhao, Y., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116945 · Cited by 1
“8 Some palliative treatments such as vitamin E or polyene phosphatidyl choline were recommended for MASH patients in clinical practice in China.”
InfluentialJoy, E., & Bonnet, J. P. (2026) · American Journal of Lifestyle Medicine · doi:10.1177/15598276261450530 · Cited by 1
Singh, V., Wang, M., Ebinger, J., Velazquez, A., Cheng, S. C., Kwan, A. C., & Trivedi, H. D. (2026) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002396 · Cited by 1
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Jain, V. S., Vong, T., Thompson, V. L., Lopez-Silva, C., Sequeira, L., Rizer, N. W., Hinson, J. S., Klein, E., Copenhaver, M. S., Brookmeyer, C., et al. (2026) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2026.05.035 · Cited by 1
Chianetta, R., Giannitrapani, L., Lipari, A. G., Brunone, A., Cannizzo, C., Citarrella, R., Soresi, M., Liguori, A., Panera, N., Morisco, F., et al. (2026) · Biomolecules · doi:10.3390/biom16060797 · Cited by 2
“Adverse gastrointestinal effects, such as nausea, vomiting, and constipation, particularly with GLP-1 receptor agonists and dual agonists, may limit tolerability in some patients, especially during treatment initiation [176–178].”
Adams, L. A., Lei, S., Bertot, L. C., Schrader, S., Frear, S., Zhou, C., Heywood, S. E., & Emery, J. D. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70750 · Cited by 1
Sinusoidal endothelial cells control liver inflammation and fibrosis
Chen, Y., & He, Y. (2026) · Journal of Clinical Investigation · doi:10.1172/jci206430 · Cited by 1
“Although Resmetirom (21) and Semaglu-tide (22) have shown histologic benefit in selected patients with MASH-associated fibrosis, there are still no broadly approved antifibrotic therapies for liver fibrosis across different etiologies.”
Alali, M., Naveed, A. K., Alnounou, A., Alharami, M., & Nashed, B. (2026) · Cureus · doi:10.7759/cureus.109979 · Cited by 1
“…semaglutide produced significantly greater rates of MASH resolution without worsening of fibrosis compared with placebo, representing a landmark advance in the pharmacologic treatment of MASH and establishing GLP-1 receptor agonists as a cornerstone of emerging MASH-directed therapy [19].”
Lee, S.-H. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70349 · Cited by 1
“Glucagon-like peptide-1 receptor agonists have shown promising effects on body weight, hepatic steatosis, and MASH resolution, accompanied by signi fi cant cardiovascular risk reduction 14 .”
Incretin-based therapies: a new era in metabolic liver disease management
Elangovan, S., Cheah, C. C. M., & Goh, G. B. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.15 · Cited by 1
Chen, Y., Yang, X., Shen, W., Zhang, P., Yang, X., Xu, X., & Lu, D. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70347 · Cited by 1
“9 Followed to resmetirom, semaglutide has been the next approved drug on MASH treatment by FDA.”
MASLD as Complication of Diabetes
Stefan, N. (2026) · Diabetes · doi:10.2337/dbi26-0001 · Cited by 4
Song, D., Zhang, Z., Sheng, W., Xiang, Y., Zhang, X., Xiang, Y., Ji, G., Lu, L., & (8200), L. Z. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158422 · Cited by 1
Song, K., Zhang, Q., Li, S., Du, Q., Ng, S. K., Chen, Y., Pu, Y., Widjaja, J., Chen, H., & Chen, Y. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00726-3 · Cited by 1
Peng, T., Lin, H., Tseng, T., Wu, T., & Chao, Y. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70629 · Cited by 2
“21 This supports a potential ‘ cirrhosis ceiling effect ’ , in which advanced architectural distortion and matrix cross-linking constrain the reversibility of fibrosis.”
Therapeutic development in MASH: From accelerated approval to cirrhosis trial innovation
Dunn, W., & Alkhouri, N. (2026) · Med · doi:10.1016/j.medj.2026.101172 · Cited by 2
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management
Rubino, D., Wharton, S., Knight, M. G., & Aroda, V. R. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2686467 · Cited by 1
SUMOylation of HMGCS1 triggers its ubiquitin-dependent degradation to alleviate hepatic steatosis
Wang, M., Wu, X., Wang, T., Liu, W., Ma, Z., Zhang, Y., Zhang, X., Yin, G., Yang, W., Wu, Z., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156681 · Cited by 1
Maier, G. A., Hofmann, R. A., Roden, M., Rathmann, W., & Kuß, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71023 · Cited by 1
Self-citationEfficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome
Shahd, A., Bridges, N., & Goldstone, A. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1881392 · Cited by 1
ABDEEN, A. A., Ayer, T., Biswas, A., Wehrle, C. J., Laique, S. N., & Aminian, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71020 · Cited by 1
METTL1 promotes hepatic steatosis by mediating m7G modification of ALOX15B mRNA
Li, L., 孙元海, Li, L., Zheng, W., Bian, J., & Li, H. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124559 · Cited by 1
Paleček, J., Hříbek, P., Žďarská, D. J., Novàkovâ, M., Skořepa, P., & Urbánek, P. (2026) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/209813 · Cited by 1
Liu, L., Niu, J., Sun, Y., He, Z., Jiao, Z., Li, G., Wang, G., Luo, F., & Li, W. (2026) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2025.181 · Cited by 1
Andrés‐Rozas, M., Aristu-Zabalza, P., Chullo, G., Liu, G., Fundora, Y., Villa, R., Lopez, J., Folguera, C., Fernández‐Iglesias, A., Guixé‐Muntet, S., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119711 · Cited by 1
Andrés‐Rozas, M., Guixé‐Muntet, S., & Gracia‐Sancho, J. (2026) · Liver International · doi:10.1111/liv.70794 · Cited by 1
“Notably, the currently approved semaglutide dose for patients with MASH and fibrosis stages F2–F3 is 2.4 mg/week [2], a dosage at which antifibrotic effects have been demonstrated in humans and which corresponds to approximately 70 μg/kg/day in mice, exceeding the dose used by Gonzalez-Rellan et…”
InfluentialHigh‐Throughput Quantitative Chemical Shift‐Encoded MRI of the Liver
Fullerton, G. C., Tang, J., Starekova, J., Heidenreich, J. F., Pirasteh, A., Harris, D. T., Tamada, D., Buelo, C. J., Rettmann, D. W., Hernando, D., et al. (2026) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70429 · Cited by 1
Holleboom, A. G., & Schattenberg, J. M. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101957 · Cited by 1
“28,63 The question may ultimately become not whether”
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
Worthington, J., Kelly, A., He, E., George, J., Adams, L. A., & Feletto, E. (2026) · Value in Health · doi:10.1016/j.jval.2026.06.018 · Cited by 1
He, B., Wang, N., Yan, R., Jiao, J., Zhang, H., Huang, Q., 席奇, Chang, Z., Guan, X., Yan, S., et al. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1803238 · Cited by 1
Joshi, S., Samajdar, S. S., Gupta, A., Bhartia, M., Lodha, S., Bhattacharyya, S., Seshadri, K. G., Nagendra, L., Unnikrishnan, A. G., PADHYE, D. A., et al. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1733995 · Cited by 1
Jiménez-González, C., Iruzubieta, P., Alonso‐Peña, M., Cayon, L., & Crespo, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1884657 · Cited by 1
“The recent approval of resmetirom (Harrison et al., 2024) and semaglutide (Sanyal et al., 2025) for MASH with F2–F3 fibrosis also opens the possibility of including statins as an active arm or in combination in pragmatic trials.”
Yang, X., Cheng, K., Chen, C., Zhang, Y., & Wang, D. W. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177734 · Cited by 1
“Semaglutide improves symptoms and physical function in obesity-related HFpEF and has demonstrated histological efficacy in MASH [159,160].”
Shrestha, R., Kovacevich, A., Yerneni, H., Shroff, P., & Sajatovic, M. (2026) · Psychiatric Annals · doi:10.3928/00485713-20260701-01 · Cited by 1
Karsdal, M. A., Bay‐Jensen, A., Rasmussen, D. G. K., Krag, A. A., Johansen, S., Anstee, Q. M., Leeming, D. J., Genovese, F., Sanyal, A. J., Bager, C. L., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.07.016 · Cited by 1
Self-citationReframing MASLD: A Hepatic Condition With Systemic Clinical Impact
Castillo-Flores, P. S. N., Rodríguez‐Antonio, I., Uribe, M., Chávez-Tapia, N. C., Montalvo-Jave, E. E., & Nuño‐Lámbarri, N. (2026) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2026.103631 · Cited by 2
Ballerio, M., Minoretti, P., & Emanuele, E. (2026) · Clinics and Practice · doi:10.3390/clinpract16080137 · Cited by 1
“Specifically on the hepatic component of this dimension, the ESSENCE trial has added direct histological evidence, with semaglutide producing resolution of steatohepatitis in 62.9% of treated patients compared with 34.3% on placebo, and reduction in liver fibrosis in 36.8% versus 22.4% [76].”
InfluentialVozza, A., Biagi, F., Chiara, R., Vizzutti, F., & Marra, F. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04456-1 · Cited by 1
Hypothalamic Control of Liver Health and Disease: From Circuits to Pathophysiology and Therapies
Tang, Q., Li, J., Song, H., Zhang, A., Zeng, H., Xu, Y., Mo, L., & He, J. (2026) · Advanced Science · doi:10.1002/advs.76747 · Cited by 1
“[ 199 ].”
Ma, Y., Gao, X., Wang, J., Li, L., Huang, Z., & Li, F. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70371 · Cited by 1
Autophagy in MASLD : A Metabolic and Precision Medicine Perspective
Cazzaniga, A., Frigo, S., Cherubini, A., Rrapaj, E., & Valenti, L. V. C. (2026) · Liver International · doi:10.1111/liv.70816 · Cited by 1
Risk stratification of MASLD/MASH in type 2 diabetes: a pragmatic endocrinology outpatient pathway
Cai, Y., Zeng, F., & Liu, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1922533 · Cited by 3
Kushner, P. R., & Michos, E. D. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.049727 · Cited by 2
MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice
Li, S., Toutoungy, M., Patel, J., Bhavsar‐Burke, I., & VanWagner, L. B. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01380-9 · Cited by 2
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2714267 · Cited by 1
“The ESSENCE (part 1) study [5] lasted 72 weeks, and the second part of the study is ongoing to evaluate the long-term effects and outcomes.”
InfluentialFudim, M. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.05.043 · Cited by 1
Metabolic dysfunction-associated steatotic liver disease in women across the life course
Okigbo, C. C., Springel, E. H., Blaney, H. L., & Sanyal, A. J. (2026) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/s3050-5038(26)00177-9 · Cited by 1
Self-citationVignera, S. L., & Condorelli, R. A. (2026) · Pharmaceuticals · doi:10.3390/ph19081236 · Cited by 1
“More recently, s.c. semaglutide 2.4 mg has also received regulatory approval for MASH with moderate-to-advanced liver fibrosis (F2–F3), further underscoring the pleiotropic potential of GLP-1 receptor agonism [9].”
InfluentialInterorgan Crosstalk in MASLD: A Narrative Review
Lonardo, A., & Weiskirchen, R. (2026) · Biomedicines · doi:10.3390/biomedicines14091949 · Cited by 1
Liu, J., & Wu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1879097 · Cited by 2
“Semaglutide 2.4 mg later reported phase 3 benefit and received accelerated United States approval for adults with noncirrhotic MASH and moderate-to-advanced fibrosis (Sanyal et al., 2025; U.S. Food and Drug Administration, 2025).”
InfluentialAugusto, M., Bauer, R., Clancy, S., Poulsen, A., Tefos, F., & Long, M. T. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101993 · Cited by 1
Self-citation
Metadata
- Authors
- Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V.
- Affiliations
- Virginia Commonwealth University (US)
- King's College London (GB)
- Novo Nordisk (Denmark) (DK)
- University of Turin (IT)
- University of Chicago (US)
- Düsseldorf University Hospital (DE)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-05
- Volume
- 392
- Issue
- 21
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409963211
- Cited by
- 1,115
- References
- 39
- Citations by year
- 2026: 813 · 2025: 302
- FWCI
- 767.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, nonalcoholic steatohepatitis, GLP-1 receptor agonists, liver fibrosis, weight loss, body mass index, non-alcoholic fatty liver disease, fibrosis regression, interim analysis, multiple testing correction, non-invasive fibrosis markers
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Biopsy, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.